MeiraGTx Holdings plc (MGTX)
NASDAQ: MGTX · Real-Time Price · USD
7.43
-0.15 (-1.98%)
Mar 3, 2026, 4:00 PM EST - Market closed
MeiraGTx Holdings Revenue
MeiraGTx Holdings had revenue of $410.00K in the quarter ending September 30, 2025, a decrease of -96.24%. This brings the company's revenue in the last twelve months to $27.42M, up 96.83% year-over-year. In the year 2024, MeiraGTx Holdings had annual revenue of $33.28M with 137.42% growth.
Revenue (ttm)
$27.42M
Revenue Growth
+96.83%
P/S Ratio
21.81
Revenue / Employee
$67,034
Employees
409
Market Cap
598.05M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 33.28M | 19.26M | 137.42% |
| Dec 31, 2023 | 14.02M | -1.90M | -11.95% |
| Dec 31, 2022 | 15.92M | -21.78M | -57.77% |
| Dec 31, 2021 | 37.70M | 22.14M | 142.25% |
| Dec 31, 2020 | 15.56M | 2.27M | 17.09% |
| Dec 31, 2019 | 13.29M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rigel Pharmaceuticals | 282.08M |
| Lexicon Pharmaceuticals | 70.86M |
| Ocugen | 5.37M |
| YD Bio | 510.36K |
| Allogene Therapeutics | 22.00K |
MGTX News
- 4 weeks ago - ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy - PRNewsWire
- 3 months ago - Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference - PRNewsWire
- 3 months ago - MeiraGTx Reports Third Quarter 2025 Financial and Operational Results - GlobeNewsWire
- 3 months ago - MeiraGTx: Latest Eli Lilly Partnership Ignites Riboswitch Technology Potential - Seeking Alpha
- 4 months ago - Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease - Reuters
- 4 months ago - MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology - GlobeNewsWire
- 5 months ago - MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress - GlobeNewsWire
- 5 months ago - MeiraGTx: Hologen Partnership Makes Parkinson's Gene Therapy Vital - Seeking Alpha